36
Participants
Start Date
June 30, 2025
Primary Completion Date
August 31, 2027
Study Completion Date
August 31, 2028
Nanoliposomal irinotecan
Nanoliposomal Irinotecan 50 mg/m2 will be administered over 90 minutes (± 10 minutes) IV. All subjects must be pre-medicated prior to nanoliposomal irinotecan infusion with standard doses of dexamethasone and a 5-HT3 antagonist, or equivalent other anti-emetics (according to standard institutional practices).
Oxaliplatin
Oxaliplatin 60 mg/m2 will be administered over 120 minutes (± 10 minutes) IV. Institutional standards may be used for all aspects of oxaliplatin administration including premedication administration.
5 fluorouracil
5-FU will be administered as a continuous infusion over 46 hours. Subjects will go home with an infusion pump and return to clinic at the end of infusion for removal of the pump or, if possible, the pump may be removed at the subject's home (except on Cycle 1 Day 3).
Leucovorin
Leucovorin 400 mg/m2 will be administered over 30 minutes IV.
RECRUITING
Virginia Commonwealth University, Richmond
RECRUITING
Moffitt Cancer Center, Tampa
RECRUITING
University of Illinois Cancer Center, Chicago
RECRUITING
Washington University School of Medicine, St Louis
Collaborators (1)
Ipsen
INDUSTRY
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Tiago Biachi de Castria
OTHER